Insmed Incorporated (insm)
INSM — Company Overview
Insmed Incorporated (INSM) trades on NMS as part of the Healthcare peer group (Biotechnology).
| Ticker | INSM |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NMS |
| Market cap | $25.84B |
| Last price | $118.34 |
| Size category | Large Cap |
INSM — Business Description
INSM represents a Biotechnology business in the Healthcare segment. Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppu…
Official website: https://www.insmed.com.
INSM — Investment Thesis
At a high level, INSM offers exposure to Healthcare with metrics outlined below from public market data.
- Revenue is expanding at roughly 3.0% year-over-year (public data).
- Equity market capitalization is approximately $25.84B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
INSM — Financial Health
Key financial health indicators for Insmed Incorporated are derived exclusively from public data — no proprietary estimates.
Negative profit margin (-76.9%) signals near-term profitability pressure. Negative free cash flow of $-571.82M may require careful capital allocation.
| Forward P/E | 154.38× |
| Price / Sales | 22.72× |
| Price / Book | 34.10× |
| Gross margin | 83.5% |
| Operating margin | -23.8% |
| Profit margin | -76.9% |
| Return on equity | -87.2% |
| Debt / Equity | 97.65 |
| Free cash flow | $-571.82M |
INSM — Growth Outlook
Growth outlook for Insmed Incorporated (INSM) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 3.0% indicates strong top-line momentum.
- Price is 44.4% below the 52-week high.
INSM — Competitive Position
Insmed Incorporated (INSM) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Biotechnology.
- Market capitalization of $25.84B places INSM among large-cap peers.
- Gross margin near 83.5% may reflect pricing power or favorable mix.
INSM — Strengths
Strengths for Insmed Incorporated (INSM) inferred from public financial metrics:
- Revenue growth of 3.0% year-over-year.
- Gross margin of 83.5% supports competitive unit economics.
- Large Cap scale ($25.84B) may provide distribution and funding advantages.
INSM — Weaknesses
Weaknesses and pressure points for Insmed Incorporated (INSM) based on available data:
- Thin profit margin (-76.9%).
- Negative free cash flow ($-571.82M).
- Price 44% below the 52-week high — sustained negative sentiment.
INSM — Opportunities
- Sustained revenue growth (3.0%) could support multiple expansion if margins hold.
INSM — Risks
- Thin margins leave less room for operational missteps.
INSM — Summary
Insmed Incorporated (INSM) is a large-cap Healthcare company focused on Biotechnology, listed on NMS. Last price $118.34 with market cap $25.84B. Revenue grew 3.0% year-over-year per public data. Notable strengths include revenue growth of 3.0% year-over-year. Key watch items include thin profit margin (-76.9%). Premium Terminal tools for Insmed Incorporated add ownership analytics, news, and richer estimate history beyond this public summary.
Start Free — open INSM in Vest Terminal
Access live data, filings, ownership, and analysis for Insmed Incorporated.
Insmed Incorporated FAQ
What does Insmed Incorporated (INSM) do?
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is…
What is INSM's P/E ratio?
Insmed Incorporated has a trailing P/E of N/A× based on publicly available market data.
Does INSM pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is INSM in?
Insmed Incorporated is classified in Healthcare (Biotechnology) on NMS.
What is INSM's market capitalization?
Approximate market cap: $25.84B.
What are the main risks for INSM?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of INSM?
Potential positives include revenue growth of 3.0% year-over-year, gross margin of 83.5% supports competitive unit economics.
Where can I get analyst estimates for INSM?
Public analyst price targets and consensus for Insmed Incorporated are on the free /stocks/insm/estimates page. Deeper estimate history and models are available in Vest Terminal.